The Fcc receptor IIIA (FccRIIIA) has traditionally been known as a positive regulator of immune responses. Consistent with this, mice deficient in FccRIIIA are protected from various inflammation-associated pathologies including several autoimmune diseases. In contrast to this accepted dogma, we show here that mice lacking FccRIIIA developed increased rather than reduced both humoral and cellular immune responses to mucosal (sublingual) immunization with ovalbumin (OVA) given together with the strong mucosal adjuvant cholera toxin as well as to parenteral (subcutaneous) 
Introduction
The Fc gamma receptor (FccR) family is widely expressed on many immune cells, where these receptors help to regulate both innate and adaptive immunity. In both mice and humans, the family consists of several activatory FccRs, one of which is FccRIIIA, and a single recognized inhibitory receptor, FccRIIB. Both FccRIIIA and FccRIIB are expressed on all myeloid cells including mast cells, basophils, eosinophils, neutrophils, monocytes/macrophages and dendritic cells; FccRIIB is in addition also expressed on B cells [1] .
FccRIIIA and FccRIIB have two 95% identical Ig-like extracellular domains that are capable of binding the Fc portion of IgG [2] . FccRIIIA is composed of an IgG-binding a-chain and a signal-transducing adaptor molecule that contains a homodimer of the common FcRc-chain. The FcRc-chain contains an immunoreceptor tyrosine-based activation motif (ITAM) that becomes phosphorylated following ligand engagement of the receptor, leading to docking and activation of protein tyrosine kinases such as spleen tyrosine kinase (SYK). In contrast, FccRIIB is composed of a single a-chain which contains an intracytoplasmic immunoreceptor tyrosinebased inhibitory motif (ITIM) which negatively regulates cell activation through activation of phosphatases such as Src homology 2-containing inositol 5 0 -phosphatase (SHIP).
Consistent with a normally activating role of FccRIIIA, defective NK cell-mediated antibody-dependent cytotoxicity, macrophage phagocytosis of IgG-coated particles and mast cell degranulation triggered by IgG immune complexes have been observed following genetic deletion of FccRIIIA [3] . Furthermore, both passive cutaneous and passive systemic anaphylaxis induced by IgG immune complexes are compromised in FccRIIIA À/À mice [3, 4] .
FccRIIIA À/À mice are also protected, to variable degrees, in experimental models of arthritis [5] [6] [7] , atherosclerosis [8, 9] , acute glomerular inflammation [10] , antibodydependent type II autoimmunity [11] , experimental autoimmune encephalomyelitis [12] , anti-erythrocyte IgG-mediated anaemia [13] and nephrotoxic nephritis [14] . Further, FccRIIIA has been found to be important for Th2-mediated airway inflammation [15] and anaphylatoxin-induced lung pathology [16] . However, in contrast to the classically defined activatory role of FccRIIIA, new evidence indicates that ITAMcontaining receptors can generate a mixture of activation and inhibition signals [17] . The ITAM that transduces inhibitory signals dampening immune responses is specifically designated as ITAMi [18] . FccRIIIA engagement by antibodies of the IgG1 subclass may result in partial phosphorylation of ITAM tyrosine residues following the recruitment of Src homology 2 domain-containing phosphatase-1 (SHP-1) recruitment, thus favouring the ITAMi configuration [18, 19] .
The effect of FccRIIIA on antigen-specific cellular and humoral immune responses following immunization has however not been systematically investigated. In this study, we explored such responses in FccRIIIA-deficient mice in comparison with wild-type (WT) and FccRIIBdeficient mice after mucosal immunization with a model protein antigen (ovalbumin, OVA) together with the strong mucosal adjuvant cholera toxin (CT), as well as after parenteral immunization with OVA in complete Freund's adjuvant (CFA). Interestingly, in both systems, we observed strongly enhanced rather than suppressed antigen-specific humoral and cellular immune responses in FccRIIIA-deficient mice compared with WT mice, with the enhancement of these responses in the FccRIIIA À/À mice being of similar magnitude as seen in concomitantly immunized FccRIIB-deficient mice.
Materials and methods
Mice. FccRIIIA À/À mice on the C57BL/6 background were originally purchased from The Jackson Laboratory and bred in-house at the MIVAC breeding unit of the experimental animal facility of the University of Gothenburg as were FccRIIB À/À mice on the C57BL/6 background kindly donated by Dr Ken Smith, Cambridge University [20] . Also OT-II mice, whose T cells have a transgenic T cell receptor specific for the 323-339 peptide of ovalbumin (OVA 323-339 ), were obtained from the MIVAC breeding unit. Six-to eight-week-old female mice at the start of experiments were used, and all mice, including C57BL/6 WT control mice (purchased from B&K Universal AB, Stockholm, Sweden), were housed together under specific pathogen-free conditions at the experimental animal facility from at least 2 weeks before and for the duration of the experiments. The studies were approved by the Enzyme-linked immunosorbent assay. To determine serum OVA-specific total IgG as well as IgG1 and IgG2c antibody titres, enzyme-linked immunosorbent assays (ELISA) were performed as described previously [21] . Endpoint titres were expressed as the reciprocal log 10 of the extrapolated dilution giving an absorbance at 450 nm of 0.4 above the background after a 20-min incubation with the enzyme substrate.
Stimulation of T cells by co-cultured DCs. Bone marrowderived DCs were generated by incubating bone marrow cells isolated from naive WT, FccRIIB À/À or FccRIIIA À/À mice in the presence of 200 ng/ml Flt3-L (Purchased from R&D System) for 9 days. The DCs were then incubated for 2 h in medium alone, in medium containing 20 lg/ml OVA or medium containing immune complexes generated by pre-incubation of 20 lg/ml OVA with 30 lg/ml anti-OVA IgG1 (Sigma), followed by rigorous cell washing. Next, the treated DCs (2 9 10 4 /well) were co-cultured with freshly isolated OT-II T cells (1 9 10 5 /well) for 3 or 4 days with [ 3 H]-thymidine being added during the last 6 h of co-culture. T cell proliferation was determined by a radioactive assay based on incorporation of [ 3 H]-thymidine, and expansion of Foxp3 À CD25 + CD4 + T effector cells was analysed by flow cytometry.
Flow cytometric staining and analyses. Single-cell suspensions from spleens or PLNs were prepared as described [22] . For staining of surface markers, cells were incubated with antibodies with appropriate fluorochrome conjugation (Table S1 ) to mouse CD1d, CD4, CD5, CD25, CD103, CD69, CD138, B220, CD11c, CD19, CD80, CD62L, CD86, ICOS, CXCR5, PD-1, CD38 and GL7 (BD or eBioscience, San Diego, CA, USA, or Biolegend, San Diego, CA, USA). For detection of FccRIIB expression, cells were stained with FITC-labelled anti-FccRIIB mAb (AT130-2) [23] . For detection of cells expressing latencyassociated peptide (LAP)/TGF-b, cells were stained with biotinylated anti-LAP Ab (R&D Systems, Oxen, UK), followed by streptavidin-allophycocyanin, in addition to staining with Abs against selected surface markers before flow cytometric analysis. For detection of intracellular Foxp3, cells were fixed and permeabilized with Cytofix/ Cytoperm solution (eBioscience) according to the manufacturer's recommended protocol, followed by incubation with FccR block for 15 min and thereafter an allophycocyanin-conjugated anti-Foxp3 antibody (Clone FLK-16; Nordic Biosite) at 4°C for 30 min in the dark. Cells were analysed by an LSR II flow cytometer (BD Pharmingen, San Jose, CA, USA). The gating strategies are shown in Figure S1 . Data were analysed by FlowJo software (Tree Star, Ashland, OR, USA).
Statistics. Unpaired Student's t-tests (two-tailed) were used to calculate statistical differences between experimental and control groups.
Results
Increased B cell and antibody responses in FccRIIIA-deficient mice compared to WT mice after mucosal immunization with OVA and CT To evaluate the importance, if any, of FccRIIIA on the development of humoral and cellular immune responses after mucosal immunization, we immunized FccRIIIAdeficient mice twice with OVA together with the strong mucosal adjuvant CT and compared the responses 10 days after the second dose with those seen in concomitantly immunized WT and FccRIIB-deficient mice. In the WT mice, this immunization regimen elicited a high-titred serum IgG anti-OVA antibody response which, as expected, was even further (15- (Fig. 1C) . This is possibly associated with the role of FccRIIB on induction of apoptosis of B cells [20, 25, 26] , such that the lack of FccRIIB might result in persistence of B cells under steady-state conditions. The levels of splenic T follicular helper (Tfh) cells, which contribute to classswitch recombination, somatic hypermutation and memory B cell development in the germinal centre [27, 28] , were similar in mice of all three genotypes (Fig. 1D ).
Effector T cell responses are enhanced in FccRIIIA À/À mice after mucosal immunization
The mucosal immunization with OVA plus CT induced OVA-specific spleen T cell proliferative responses at similar levels in FccRIIIA À/À as in WT mice, but of lesser magnitudes than achieved in FccRIIB À/À mice ( Figure S3 ). In contrast, the frequencies of Foxp3
+ effector T cells were increased to significantly higher levels in both FccRIIIA À/À and FccRIIB À/À mice than in WT mice ( Fig. 2A) . As expected when CT is used as an adjuvant [29] , immunization downregulated the production of Foxp3 + Treg cells in WT and, to a lesser extent, in FccRIIB À/À mice, whereas this effect on Treg cells was compromised in FccRIIIA À/À mice (Fig. 2B ).
Similar to the Foxp3 + Treg cell responses, TGFb + CD1d + CD5 + B cells which are also known to have an inhibitory-regulatory function were reduced after immunization with OVA adjuvanted with CT in WT mice and to a lesser extent in FccRIIB À/À mice, while the frequency of these regulatory B cells was instead slightly increased in FccRIIIA À/À mice after immunization (Fig. 2C) . (Fig. 2D) . When CD86 + CD38 + memory B cells were examined separately, they increased to higher levels in both FccRIIB À/À and FccRIIIA À/À mice than in WT mice (Fig. 2E) , whereas the increase in CD86 + cells in DCs was similar in all the three strains of mice (Fig. 2F) .
The modulation of the expression of one FccR may affect that of other FccRs [30] . (Fig. 3A) . Similar to the findings after s.l. immunization, these antibodies were predominant of the IgG1 subclass and IgG2c anti-OVA antibodies were in fact reduced rather than increased in the FccRIIIA À/À mice compared to the WT mice (Fig. 3B) , both in absolute terms and even more pronounced when comparing their levels relative to the IgG1 antibody titres. Thus, while the IgG2c titres were 20-fold lower than the IgG1 titres in the WT mice, they were 60-fold lower in the FccRIIB À/À mice and as much as 500-fold less in the FccRIIIA À/À mice (Fig. 3B ). In the s.c. immunized FccRIIIA À/À mice, similar to the findings after mucosal immunization, the overall enhanced humoral immune response was accompanied with increased expansion of Foxp3 À CD25 + CD4 + effector T cells in draining lymph nodes (Fig. 3C) . These observations support a suppressive role of FccRIIIA also in mice immunized by s.c. injection with OVA emulsified in CFA.
FccRIIIA expression on DCs contributes to Ag-specific T cell responses
The mechanisms that may account for the enhanced immune responses in FccRIIIA À/À mice described here remain to be determined. As neither B cells nor T cells express FccRIIIA, the immune-enhancing effects leading to augmented effector responses involving these cells (e.g. antigen-specific antibody production, B and T cell ............................................................................................................................................................... 
activation) in the FccRIIIA
À/À mice are most likely secondary to modulation of FccRIIIA-expressing immune cells such as APCs. To evaluate whether the loss of FccRIIIA on DCs affects their in vitro induction of Agspecific T cell responses, we pulsed bone marrow dendritic cells generated from WT, FccRIIB À/À and FccRIIIA À/À mice with either OVA or OVA/anti-OVA IgG immune complexes followed (after extensive washing of the DCs) by co-culture of the treated DCs with freshly isolated CD4 + T cells from OT-II mice. We observed an enhanced capacity of DCs from both FccRIIB-and FccRIIIA-deficient mice in comparison with DCs from WT mice to stimulate OVA-specific T cell activation with regard to both proliferation (Fig. 4A ) and effector T cell expansion (Fig. 4B) , which was most pronounced when DCs had been pulsed with the OVA/anti-OVA IgG immune complexes (Fig. 4A, B) .
Discussion
The strong enhancement of both antibody and cellular immune responses in FccRIIIA À/À mice demonstrated in this study after both mucosal and parenteral immunization supports the paradigm that FccRIIIA is not obligatorily an activating FccR but may also or alternatively signal through ITAMi to suppress immune responses [17, 18] . In our immunization models using two strong adjuvants, CT for mucosal immunization and CFA for systemic immunization, the augmented antigen-specific immune responses in FccRIIIA À/À mice may reflect a predominating abrogation of the usual ITAMi signalling in WT mice.
In preliminary experiments, we have found that in WT DCs treatment in vitro with OVA plus CT reduced the formation of inhibitory SHP-1 by 60-80% compared with DCs treated with OVA only, and instead increased the activating signalling SYK by 40-60% (unpublished data; Lerena M, Sun J-B, Xiang Z & Holmgren J). Consistent with the role of IgG1 in partial phosphorylation of ITAM tyrosine residues following the recruitment of SHP-1 that favours the ITAMi configuration [18] , it has been reported in both human and mouse models that intravenously administered IgG (IVIg), which has IgG1 as its most abundant subclass, may generate inhibitory signals to suppress inflammatory responses through targeting FccRIIIA [19] . Mouse IgG1 is much less pathogenic compared with IgG2b in autoimmune haemolytic anaemia mediated through FccRIIIA [13] . FccRIIIA À/À mice are resistant to Leishmania mexicana infection in which the initial antibody response to the parasite is predominantly IgG1 which appears to suppress protective immunity in WT mice through binding to FccRIIIA [31] . IgG1-mediated inhibition of osteoclastogenesis by FccRIII has also been observed [32] . We have previously demonstrated that IgG1-containing immune complexes fail to activate mast cells in contrast to IgG2a and IgG2b complexes [33] . .......................................................................................................................................................... mice [35] . We believe that the immune modulatory roles of FccRIIIA are complex and that FccRIIIA may differentially impact the immune responses depending on the experimental system; the outcome of the immune effector function appears to depend on the delicate balance between the inhibitory and activating signals mediated through the engagement of this receptor.
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